Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with...

Although gemcitabine (Gem) constitutes first-line therapy for pancreatic cancer, its clinical outcome suffers from rapid metabolism and acquired drug resistance. To overcome its limitations, several lipophilic prodrugs including 4-(N)-stearoyl Gem (GemC18) have been studied for their efficacy over Gem. Herein, we aimed to prepare and characterize the GemC18-loaded poly(ethylene glycol)-poly(d,l-lactide) (PEG-PLA) polymeric micelles (PMs) as well as its self-assembled nanoparticles (NPs). A D-optimal design was also utilized to investigate the effects of formulation variables, namely initial drug/polymer ratio, total solid content, and the type of organic solvent on properties of GemC18-loaded PMs. The optimized formulation showed a particle size of about 120 nm, encapsulation efficiency >90%, and a sustained release behavior of the drug. Alternatively, the prodrug NPs were harvested in larger size (∼300 nm) and more negative zeta potential, but less chemical stability compared to the optimized PMs. In Panc-1 and AsPC-1 cell lines, both GemC18-loaded PMs and NPs were significantly more cytotoxic than GemC18 solution. Chiefly, they could effectively reduce the viability of Gem high-resistant AsPC-1 cells in culture, whereas the molar equivalent doses of Gem did not show any acceptable cytotoxicity. Thus, these results suggest a promising direction for alternative Gem delivery systems for future therapeutic applications.